Department of Laboratory Medicine, The Affiliated Hospital of Southwest Medical University, Luzhou, China.
Department of Laboratory Medicine, West China Hospital, Sichuan University, Chengdu, China.
Thorac Cancer. 2018 Jan;9(1):66-74. doi: 10.1111/1759-7714.12537. Epub 2017 Nov 1.
Previous studies have indicated that large intergenic non-coding RNA regulator of reprogramming (lincRNA-ROR) plays an important role in regulating tumor carcinogenesis and metastasis; however, whether circulating lincRNA-ROR could function as a potential biomarker for breast cancer (BC) diagnosis and monitoring is unknown. This study was conducted to investigate circulating lincRNA-ROR in plasma as a potential biomarker for BC diagnosis and monitoring.
We performed reverse transcription-quantitative-PCR to examine lincRNA-ROR expression levels in cell lines, 24 pairs of BC tissue samples, and 94 plasma samples from BC patients. Potential correlations between plasma lincRNA-ROR levels and clinicopathological characteristics were analyzed. A receiver operating characteristic curve was calculated to evaluate the diagnostic values for BC. Pearson correlation analysis of lincRNA-ROR in plasma samples and the corresponding tissues of the same patients was performed to explore tumor monitoring values.
LincRNA-ROR expression was significantly increased in BC cell lines, tissues, and plasma (all P < 0.01). Plasma lincRNA-ROR levels were associated with estrogen receptors (P = 0.042) and lymph node metastasis (P = 0.046). The area under the receiver operating characteristic curve of plasma lincRNA-ROR was 0.844 (sensitivity 80.0%, specificity 56.7%), which was higher than carcinoembryonic and carbohydrate antigen 15-3 values. Moreover, plasma lincRNA-ROR levels were decreased in postoperative compared to preoperative samples (P < 0.0001). Plasma lincRNA-ROR levels moderately correlated with the corresponding tissue level in the same patients (r = 0.638, P < 0.0001).
Plasma lincRNA-ROR may be a potential biomarker for BC diagnosis and a dynamic monitor.
先前的研究表明，大的基因间非编码 RNA 重编程调节因子（lincRNA-ROR）在调节肿瘤发生和转移方面发挥着重要作用；然而，循环 lincRNA-ROR 是否可以作为乳腺癌（BC）诊断和监测的潜在生物标志物尚不清楚。本研究旨在探讨循环 lincRNA-ROR 作为 BC 诊断和监测潜在生物标志物的作用。
我们采用反转录定量 PCR 检测细胞系、24 对 BC 组织样本和 94 例 BC 患者血浆中 lincRNA-ROR 的表达水平。分析血浆 lincRNA-ROR 水平与临床病理特征之间的潜在相关性。计算受试者工作特征曲线评估 BC 的诊断价值。对同一患者的血浆样本和相应组织进行 Pearson 相关分析，探讨肿瘤监测价值。
lincRNA-ROR 在 BC 细胞系、组织和血浆中的表达均显著升高（均 P<0.01）。血浆 lincRNA-ROR 水平与雌激素受体（P=0.042）和淋巴结转移（P=0.046）有关。血浆 lincRNA-ROR 的受试者工作特征曲线下面积为 0.844（敏感性 80.0%，特异性 56.7%），高于癌胚抗原和糖类抗原 15-3 的价值。此外，与术前相比，术后血浆 lincRNA-ROR 水平降低（P<0.0001）。血浆 lincRNA-ROR 水平与同一患者的相应组织水平中度相关（r=0.638，P<0.0001）。
血浆 lincRNA-ROR 可能是 BC 诊断的潜在生物标志物，也是一种动态监测指标。
